Pain

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, March 18, 2024
Research, Epilepsy, PO, Seizure, Partnership, Risk, Patient, Tramadol, Acquisition, American Epilepsy Society, GABAA, Enrollment, NRF1, SBMA, Schedule, Hydromorphone, Society, Therapy, DSM-IV codes, Safety, GAERS, Morphine, Pain, FDA, AES, Annual general meeting, Food, Pharmaceutical industry

MIAMI, March 18, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the year ended December 31, 2023.

Key Points: 
  • “We made considerable progress across our pipeline of differentiated neurologic therapies in 2023," said Alexandra MacLean, M.D., Chief Executive Officer of Avenue.
  • Pending additional financing, we look forward to progressing BAER-101 and IV tramadol for patients facing great unmet need.
  • R&D Expenses: Research and development expenses for the full year 2023 were $6.1 million, compared to $2.7 million in 2022.
  • G&A Expenses: General and administrative expenses for the full year 2023 were $4.2 million, compared to $5.3 million in 2022.

Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress

Retrieved on: 
Monday, March 18, 2024
Research, TNF, AON, Dexamethasone, Congress, International, International Financial Reporting Standards, Telecanthus, Inflammation, DME, Patient, SNP, NDA, American Academy, G&A, POC, Business analyst, IND, Abstract, DED, Bank statement, Genotype, Investment, Retina, Diabetic retinopathy, OCS, Safety, CHF, Pain, Stage 2, Pharmaceutical industry

Riad Sherif M.D., Chief Executive Officer of Oculis: “2023 was a remarkable milestone-rich year for Oculis.

Key Points: 
  • Riad Sherif M.D., Chief Executive Officer of Oculis: “2023 was a remarkable milestone-rich year for Oculis.
  • These non-IFRS financial measures exclude the impact of items that the Company’s management believes affect comparability or underlying business trends.
  • The Company’s management uses these measures to better analyze its financial results and better estimate its financial outlook.
  • The resulting non-cash foreign exchange impact of such reclassification amounted to CHF 5.0 million or $5.7 million for the year ended December 31, 2023.

Common Skin Cancer, Like Christie Brinkley’s, Can Often Be Cured Without Surgery

Retrieved on: 
Thursday, March 14, 2024
Skin, Skin cancer, Patient, SRT, Mohs surgery, Dermatology, Cancer, Insurance, Basal-cell carcinoma, Carcinoma, Patent, Pain, Medicare, Marketing, FDA, Food, Medical imaging

Basal cell carcinoma, which Brinkley had, and squamous cell carcinoma are forms of nonmelanoma skin cancer, the most common type of cancer in the United States.

Key Points: 
  • Basal cell carcinoma, which Brinkley had, and squamous cell carcinoma are forms of nonmelanoma skin cancer, the most common type of cancer in the United States.
  • Brinkley had Mohs surgery, the traditional treatment that dates back to the 1930s,” says dermatologist and surgeon Dr. Janine Hopkins of Hopkins Dermatology, Monroe, Louisiana and Southlake, Texas.
  • The treatment is administered over the course of 15-minute sessions, with no cutting, pain, surgical scarring or need for reconstructive surgery.
  • SkinCure Oncology recently announced receipt of a U.S. patent for a new image-guided technology that will be the fourth generation of SRT.

National Civil Rights Museum adds to roundtable slate for The Resilience: Combatting Police Violence through Policy and Public Safety

Retrieved on: 
Thursday, March 14, 2024
The Kresge Foundation, Health care, Museum, The Reckoning, Brookings Institution, Restoration, Health equity, Resilience, Education, National Civil Rights Museum, Law enforcement, Violence, City, Memphis Cook Convention Center, CNN, Reconciliation, Police, Killing of Tyre Nichols, FedEx, Safety, Workforce, Bangladesh Technical Education Board, AIR, Pain, Policy, State, Parent, Work, Drug

Memphis, TN, March 14, 2024 (GLOBE NEWSWIRE) -- The National Civil Rights Museum will host the fourth and final national convening entitled “The Resilience: Combatting Police Violence through Policy and Public Safety” on March 22, 2024 from 9:00 am to 2:00 pm at the Renasant Convention Center.

Key Points: 
  • Memphis, TN, March 14, 2024 (GLOBE NEWSWIRE) -- The National Civil Rights Museum will host the fourth and final national convening entitled “The Resilience: Combatting Police Violence through Policy and Public Safety” on March 22, 2024 from 9:00 am to 2:00 pm at the Renasant Convention Center.
  • During the symposium, participants will offer strategies and solutions to tackle police violence through policy-driven, community-led, and trauma-informed alternatives to traditional public safety methods.
  • The event includes an opening panel, facilitated sessions, and a lunch roundtable discussion:
    Opening Panel – From Pain to Purpose: The Courageous Activism of Police Violence Victims.
  • The national convening series – The Reckoning, The Resolve, The Reconciliation, and The Resilience – is made possible by the support of National Civil Rights Museum Catalyst Partners FedEx, Cummins, and The Kresge Foundation.

"Keeping New Jersey Youth Athletes Safe": Addressing the Opioid Epidemic in Youth Sports

Retrieved on: 
Thursday, March 14, 2024
Research, Prohibition, Organization, Sport, Communication, Partnership, Knowledge, Heller, FREE, Athlete, Monmouth University, Advertising, Social policy, Rutgers University, Pain, Georgian Court University, NFL, Government

The conference, “Keeping New Jersey Youth Athletes Safe,” will be held from 10 a.m. to 3 p.m. Friday, April 19, at the Golden Nugget Hotel & Casino in Atlantic City.

Key Points: 
  • The conference, “Keeping New Jersey Youth Athletes Safe,” will be held from 10 a.m. to 3 p.m. Friday, April 19, at the Golden Nugget Hotel & Casino in Atlantic City.
  • The event, being held in conjunction with Horizon Blue Cross Blue Shield of New Jersey and the Opioid Education Foundation of America, will be tailored for coaches, athletic directors, athletic trainers, and others involved in youth sports.
  • “It’s essential to educate those involved in youth sports about the potential for opioid misuse among student-athletes,” said Angelo Valente, Executive Director of PDFNJ.
  • Kolodny, also the executive director of Physicians for Responsible Opioid Prescribing, will discuss the opioid epidemic that is impacting families and communities across the country.

Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Retrieved on: 
Thursday, March 14, 2024
Principal, Ethanol, Collateral damage, Disease, Nervous system, Patient, POC, Pancreatic cancer, Clinical trial, Pain, AMIX, Medical imaging

THE WOODLANDS, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the safe completion of the first three patient procedures for its proof-of-concept (PoC) human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain.

Key Points: 
  • “We are pleased to have safely completed the first patient procedures utilizing RF ablation in a transvascular approach to reduce the pain associated with pancreatic cancer.
  • The Principal Investigator was able to navigate the catheter to the target treatment area and perform the specified ablations with no significant adverse events.
  • The primary objective of the PoC human clinical trial is to successfully ablate relevant somatic nerves and mitigate pain in patients with pancreatic cancer pain utilizing RF ablation in a transvascular approach to the nerves in the region.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the trial.

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Retrieved on: 
Wednesday, March 13, 2024
Knee, Congress, Biologics license application, Patient, ATMP, Research, World Congress, OARSI, European Medicines Agency, WOMAC, Osteoarthritis Research Society International, KOOS, Drug development, Safety, Pain, Vasopressin receptor 2, DVD-Audio, Food, Osteoarthritis, FDA, BLA, Pharmaceutical industry

TAMPA, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PCRX-201 (enekinragene inzadenovec), the company’s novel, intra-articular helper-dependent adenovirus (HDAd) gene therapy product candidate that codes for interleukin-1 receptor antagonist (IL-1Ra), for the treatment of osteoarthritis of the knee.

Key Points: 
  • PCRX-201 was well tolerated, with efficacy observed through at least 52 weeks at all doses and cohorts.
  • Preliminary 36-week data were presented at the Osteoarthritis Research Society International (OARSI) 2023 World Congress, the premier annual international forum in osteoarthritis research and treatment.
  • The 52-week data have been accepted for presentation at OARSI 2024 taking place in Vienna, Austria in April 2024 and the company expects to present 104-week efficacy and safety data later this year.
  • PCRX-201 was also granted Advanced Therapy Medicinal Products (ATMP) designation by the European Medicines Agency in May 2023.

NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia

Retrieved on: 
Wednesday, March 13, 2024
TENS, Fibromyalgia, Label, Patient, Contraindication, Sleep, Sale, Rehabilitation, Physical medicine and rehabilitation, Consultant, Pain

WOBURN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022.

Key Points: 
  • WOBURN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022.
  • “We have been pleased by the positive response to Quell Fibromyalgia from providers taking care of patients with fibromyalgia during our strategic launch phase,” said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer of NeuroMetrix.
  • In my practice, we have even had some patients report they were able to reduce pain with Quell Fibromyalgia that medications have never helped before."
  • The sale, distribution, and use of Quell Fibromyalgia is restricted to prescription use in accordance with 21 CFR 801.109.

NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals

Retrieved on: 
Wednesday, March 13, 2024
Clobetasol, NBY, Physician, Inflammation, Patient, Food and Drug Administration, NovaBay Pharmaceuticals, Pain, FDA, Ophthalmology, Food, Pharmaceutical industry

EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S.

Key Points: 
  • EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S.
  • Under the agreement, NovaBay will market Eyenovia’s clobetasol propionate ophthalmic suspension 0.05% (“Clobetasol”), a steroid indicated for the treatment of inflammation and pain following ocular surgery, through its U.S. physician-dispensed channel.
  • Eyenovia acquired the U.S. commercial rights to clobetasol propionate ophthalmic suspension 0.05% from Formosa Pharmaceuticals in August 2023.
  • This co-promotion agreement reflects our shared commitment to bring scientifically developed, cutting-edge and high-quality ophthalmic products to physicians and the patients they treat.”

Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge

Retrieved on: 
Tuesday, March 12, 2024
Dermatology, Atopic dermatitis, Inflammation, JNJ, Research, American Academy, Cancer, FABP5, Skin, FABP, Pain, Epidermis, Oxidative stress, Pharmaceutical industry

SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge .

Key Points: 
  • SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge .
  • Artelo was awarded the opportunity to present preclinical dermatology research on ART26.12 in San Diego, California, on March 11, 2024, concurrent with the American Academy of Dermatology Annual Meeting.
  • "We are pleased to have been selected to present our ART26.12 program to the J&J immuno-dermatology leadership team," said Dr. Andrew Yates, Chief Scientific Officer of Artelo.
  • “Our drug discovery program is investigating several oral, small molecule, FABP5 inhibitors,” said Professor Saoirse O'Sullivan, Vice President Translational Science of Artelo.